2023 World Conference on Lung Cancer (Posters)-EP12.01. Tepotinib and Capmatinib in Patients with MET exon 14 Skipping NSCLC: A Matching Adjusted Indirect Comparison (MAIC)

EP12.01. Tepotinib and Capmatinib in Patients with MET exon 14 Skipping NSCLC: A Matching Adjusted Indirect Comparison (MAIC) - PDF(Slides)

Back to course

Pdf Summary

This study presented at the IASLC 2023 World Conference on Lung Cancer compared the efficacy outcomes of two MET inhibitors, tepotinib and capmatinib, in patients with MET exon 14 skipping non-small cell lung cancer (NSCLC). The study used a matching-adjusted indirect comparison (MAIC) method to adjust for differences in baseline characteristics between the two patient populations. <br /><br />The results showed that in treatment-naïve (1L) patients, tepotinib had a higher objective response rate (ORR) compared to capmatinib, with a median duration of response (DOR) of 46.4 months for tepotinib versus 12.6 months for capmatinib. Tepotinib also appeared to be associated with longer progression-free survival (PFS) and overall survival (OS) compared to capmatinib. <br /><br />In previously treated (2L) patients, tepotinib again showed a higher ORR compared to capmatinib, with a median DOR of 10.2 months for tepotinib versus 9.7 months for capmatinib. Tepotinib also had a longer PFS and a potential benefit in OS compared to capmatinib. <br /><br />The findings from this MAIC analysis confirm the clinical benefit of tepotinib over capmatinib in patients with advanced MET exon 14 skipping NSCLC, particularly in the 1L setting. The differences in ORR between the two drugs may be attributed to the specific characteristics of the patient populations enrolled in the respective trials. The study concluded that tepotinib is an effective treatment option for patients with MET exon 14 skipping NSCLC, and further updates to the analysis will be conducted as new data becomes available.

Asset Subtitle

Boris Pfeiffer

Meta Tag

Speaker Boris Pfeiffer

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

MET inhibitors

tepotinib

capmatinib

MET exon 14 skipping

non-small cell lung cancer

objective response rate

progression-free survival

overall survival

treatment-naïve patients

previously treated patients